{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:28:54Z","timestamp":1748971734021},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Perampanel is a novel drug recently approved as adjunctive therapy in epileptic patients aged 12\u00a0years and older who have drug\u2010resistant partial epilepsy with and without secondary generalization. Pharmacological researches revealed that perampanel reduces neuronal excitability by a non\u2010competitive antagonistic activity against the ionotropic alpha\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazole propionic acid (<jats:styled-content style=\"fixed-case\">AMPA<\/jats:styled-content>) receptors causing modulation of glutamatergic neurotransmission. The pharmacological profile of the drug showed complete absorption following oral administration, and extensive metabolism in the liver by oxidation followed by glucuronidation with an elimination half\u2010life of approximately 53\u2013165\u00a0h (average: 105\u00a0h), allowing once\u2010daily administration. Randomized placebo\u2010controlled trials demonstrated an effective dose range of the drug, between 4 and 12\u00a0mg\/day, to significantly reduce seizure frequency in patients with partial\u2010onset seizure that are pharmacoresistant with a favorable tolerability profile. The most frequent adverse events of the drug reported in phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> clinical trials were dizziness, somnolence, fatigue, and headache. However, the data raised from the studies can give a hope that perampanel offers a valuable option as an adjuvant therapy for pharmacoresistant partial\u2010onset and secondarily generalized seizures.<\/jats:p>","DOI":"10.1111\/fcp.12081","type":"journal-article","created":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T14:31:58Z","timestamp":1397917918000},"page":"473-480","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The <scp>AMPA<\/scp> receptor antagonist perampanel is a new hope in the treatment for epilepsy"],"prefix":"10.1111","volume":"28","author":[{"given":"Ehab S.","family":"El Desoky","sequence":"first","affiliation":[{"name":"Department of Pharmacology Faculty of Medicine Assiut University 71515 Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.12.019"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70215-6"},{"key":"e_1_2_5_4_1","first-page":"19","article-title":"A review on antiepileptic agents, current research and future prospectus on conventional and traditional drugs","volume":"3","author":"Route S.K.","year":"2010","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70047-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70153-9"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(06)81006-8"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90754-5"},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: review of physiology and pathology","volume":"130","author":"Meldrun B.S.","year":"2000","journal-title":"J. Nutr."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12099"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4944-04.2005"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00803.x"},{"key":"e_1_2_5_14_1","first-page":"112","article-title":"Epilepsy: novel therapeutic targets","volume":"3","author":"Anovadiya A.P.","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(88)90153-X"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12100"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90054-B"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612024607081"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(93)90241-I"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn200033j"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90018-B"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)90016-7"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02205.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-74806-9_16"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.10.008"},{"key":"e_1_2_5_26_1","volume-title":"Fycompa public assessment report","author":"European Medicines Agency","year":"2012"},{"key":"e_1_2_5_27_1","unstructured":"Fycompa [package insert]. Woodcliff Lake NJ: Eisai R&D Management;2012. Medlibary.org site.http:\/\/medlibrary.org\/lib\/rx\/meds\/fycompa-1\/ Accessed February 3 2014."},{"key":"e_1_2_5_28_1","unstructured":"Fycompa. EPAR. Public assessment report [online]. Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002434\/human_med_001572.jsp&mid=WC0b01ac058001d124 Accessed February 1 2014."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2012.12.006"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005060"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S30129"},{"key":"e_1_2_5_33_1","article-title":"Pharmacokinetics of perampanel, a highly selective AMPA\u2010type glutamate receptor antagonist","volume":"50","author":"Templeton D.","year":"2009","journal-title":"Epilepsia"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301268u"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_5_38_1","unstructured":"Committee for Medicinal Products for Human Use.Fycompa (perampanel) assessment report. European Medicines Agency 424476 2012."},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-13.6.269"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12240"},{"key":"e_1_2_5_41_1","unstructured":"LaurenzaA. FerryJ. HusseinZ.Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Annual Meeting American Epilepsy Society. 2011 Abstract 2.231.http:\/\/www.aesnet.org\/ Accessed February 1 2014."},{"key":"e_1_2_5_42_1","unstructured":"Fycompa. Summary of product characteristics [online]. Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp.curl=pages\/medicines\/human\/medicines\/002434\/human.med.001527.jsp&med=WC0b01ac058001d124 Accessed February 1 2014."},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130203"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12527"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01588.x"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12001"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12504"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03648.x"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12493"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12492"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12081","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:24:10Z","timestamp":1696303450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,14]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/fcp.12081"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12081","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,14]]},"assertion":[{"value":"2014-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}